Dr Reddy’s Launches Low-Cost Semaglutide Generic ‘Obeda’ in India’s Booming GLP-1 Market
Dr. Reddy’s Laboratories has entered the fast-growing GLP-1 therapy segment with the launch of its semaglutide generic, Obeda, for Type…
M V Ramana
Read More